Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Polyrizon Ltd. (PLRZ)

NCM · Biotechnology

$11.26-2.78 (-19.80%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$21.1M
P/E (TTM)
EPS
$-4.01
Div Yield
52W Range
$2.88–$18.20
Beta

Company overview

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Peers in Biotechnology

All in industry →

Recent press releases

Polyrizon Ltd. has not issued a press release in this window.

SEC filings

All filings →

Polyrizon Ltd. has not filed an SEC document in this window.

Polyrizon Ltd. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31
14,032 sh● NEW
1,025 sh● NEW
13 sh● NEW

People at Polyrizon Ltd.

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
NI -$1.5M
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.